NFRM News March 16th:
National Pharmaceuticals Corp. Appoints Chief Scientific Advisor
Wednesday March 16, 2011, 9:00 am EDT
MIAMI, FLORIDA--(Marketwire - 03/16/11) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" announced today that it has appointed Dr. Gary Yalloway as its Chief Scientific Advisor.
Dr. Yalloway is a well known leading researcher on cytokines and growth factors. He has designed the production of GLB333 through recombinant technologies at Globe Laboratories where he currently is the Chief Operating Officer and Head of all Technologies. He brings to NFRM over 14 years of multidisciplinary research experience and skills in protein engineering and the structural functional relationships of proteins of medical and industrial interest.
Dr. Yalloway earned his Ph.D. from University College, Dublin, Ireland and was a post doctoral fellow at the Institute for Biophysical Chemistry, Frankfurt, Germany and the University of British Columbia, Vancouver, Canada. Dr Yalloway was also a postdoctoral research associate at Simon Fraser University where he was lab manager and a team leader responsible for the project management of junior scientists. He served as senior research officer at Chemokine Therapeutics.
"Dr. Yalloway has outstanding skills and vast experience in biopharmaceutical drugs development.", said Elaine Affleck, President of National Pharmaceuticals Corp. "We are pleased to have Dr. Yalloway lead our scientific team and supervise the development of GLB333", Added Ms. Affleck.
&i=p28431192882&a=152722836&r=2417)
